Skip to main content


Figure 6 | BMC Cancer

Figure 6

From: Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3

Figure 6

Proposed mechanism of Meso-TR3’s pro-drug properties. The mesothelin moiety of Meso-TR3 partially interferes with an unrestricted interaction of the TR3 domain and its death receptors (left panel). In the presence of MUC16 on the cancer cell surface, the mesothelin targeting domain is removed from the TR3 surface thus enabling unrestricted access to and full activation of the death receptor-mediated extrinsic death pathway (right panel).

Back to article page